Sumitomo Mitsui Trust Holdings Inc. decreased its stake in shares of Express Scripts (NASDAQ:ESRX) by 0.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,903,912 shares of the company’s stock after selling 14,756 shares during the period. Sumitomo Mitsui Trust Holdings Inc. owned approximately 0.34% of Express Scripts worth $131,522,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently made changes to their positions in the company. Aurora Investment Counsel purchased a new position in shares of Express Scripts during the fourth quarter valued at approximately $2,317,000. Polianta Ltd increased its holdings in Express Scripts by 38.9% during the fourth quarter. Polianta Ltd now owns 20,700 shares of the company’s stock valued at $1,545,000 after buying an additional 5,800 shares during the last quarter. DnB Asset Management AS increased its holdings in Express Scripts by 3.7% during the fourth quarter. DnB Asset Management AS now owns 320,444 shares of the company’s stock valued at $23,918,000 after buying an additional 11,300 shares during the last quarter. Investors Asset Management of Georgia Inc. GA ADV purchased a new stake in Express Scripts during the fourth quarter valued at approximately $233,000. Finally, Sawyer & Company Inc purchased a new stake in Express Scripts during the fourth quarter valued at approximately $559,000. 88.20% of the stock is currently owned by hedge funds and other institutional investors.
Express Scripts traded down $0.14, reaching $76.21, during mid-day trading on Friday, Marketbeat.com reports. 66,764 shares of the company’s stock traded hands, compared to its average volume of 4,780,718. The company has a market cap of $41.42 billion, a price-to-earnings ratio of 10.63, a PEG ratio of 0.93 and a beta of 0.98. The company has a quick ratio of 0.56, a current ratio of 0.69 and a debt-to-equity ratio of 0.81. Express Scripts has a 12-month low of $73.16 and a 12-month high of $73.65.
In related news, VP Everett Neville sold 4,895 shares of the firm’s stock in a transaction dated Thursday, March 1st. The shares were sold at an average price of $75.26, for a total value of $368,397.70. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Christine Houston sold 19,889 shares of the stock in a transaction dated Thursday, March 15th. The stock was sold at an average price of $76.69, for a total transaction of $1,525,287.41. The disclosure for this sale can be found here. Corporate insiders own 0.79% of the company’s stock.
A number of analysts have commented on the stock. Barclays reduced their target price on shares of Express Scripts from $84.00 to $83.00 and set an “equal weight” rating for the company in a report on Thursday, May 3rd. Robert W. Baird set a $92.00 target price on shares of Express Scripts and gave the company a “buy” rating in a report on Thursday. Sanford C. Bernstein lowered shares of Express Scripts from a “market perform” rating to an “underperform” rating and upped their price target for the stock from $55.80 to $77.50 in a research report on Tuesday, January 30th. BidaskClub lowered shares of Express Scripts from a “hold” rating to a “sell” rating in a research report on Friday, May 11th. Finally, Jefferies Group set a $91.00 price target on shares of Express Scripts and gave the stock a “buy” rating in a research report on Wednesday, February 28th. Five equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and five have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $82.50.
About Express Scripts
Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services.
Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.